Form 4: Crinetics Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock at $43.86 per share on June 10, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 10, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of the company's common stock.
• The shares were sold at a price of $43.86 per share.
• The transaction was executed automatically under a Rule 10b5-1 trading plan previously adopted by Mr. Betz.
• Following the transaction, Mr. Betz still beneficially owns 83,643 shares of Crinetics Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding a stock sale by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the existence of a 10b5-1 plan suggests it was pre-planned and not based on current company performance.

Key Dates